Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients by D. J. A. R Moes et al.
PHARMACOGENETICS
Population pharmacokinetics and pharmacogenetics of once daily
tacrolimus formulation in stable liver transplant recipients
D. J. A. R Moes1 & S. A. S van der Bent2 & J. J. Swen1 & T. van der Straaten1 &
A. Inderson2 & E. Olofsen3 & H. W. Verspaget2 & H. J. Guchelaar1 &
J. den Hartigh1 & B. van Hoek2
Received: 24 April 2015 /Accepted: 5 October 2015 /Published online: 31 October 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Purpose The once daily formulation of tacrolimus is an im-
portant immunosuppressive drug. Interpatient variability in
metabolism has been related to genetic variation in CYP3A4
and CYP3A5. However, in liver transplantation, both donor
and recipient genotypes may affect pharmacokinetics. The
primary objective of this study was to investigate the effect
ofCYP3A4*22 and CYP3A5*3 of both donor and recipient on
once daily tacrolimus pharmacokinetics. The secondary ob-
jective was to develop a limited sampling model able to accu-
rately predict exposure.
Methods Stable liver transplant patients receiving once daily
tacrolimus (N = 66) were included. Population pharmacoki-
netic analysis was performed with patients of whomDNAwas
available (N = 49), and demographic factors, CYP3A4*22 and
CYP3A5*3, were tested as covariates. Moreover, a limited
sampling model was developed using data of 66 patients.
Results Pharmacokinetics was best described by a two-
compartment model with delayed absorption. CYP3A5*1
carrying recipients engrafted with a CYP3A5*1 carrying liver
had an average 1.7-fold higher clearance compared to non-
carriers. CYP3A5*1 carrying recipients engrafted with a
CYP3A5*1 non-carrying liver or vice versa showed an aver-
age 1.3-fold higher clearance compared with non-carriers.
CYP3A4*22 was not significantly associated with once daily
tacrolimus pharmacokinetics. Using 0, 2, and 3 h postdose as
limited sampling model resulted in significantly improved
prediction of tacrolimus exposure compared with trough
concentration.
Conclusions Both donor and recipient CYP3A5 genotype sig-
nificantly influences tacrolimus once daily pharmacokinetics.
In contrast, CYP3A4*22 appears not suitable as biomarker.
The developed limited sampling model can be used to accu-
rately estimate tacrolimus once daily exposure.
Keywords Once daily tacrolimus . Advagraf . Population
pharmacokinetics . Pharmacogenetics . Liver transplantation
Introduction
Prolonged release tacrolimus (Advagraf®) is currently in
many centers for the standard formulation of the calcineurin
inhibitor tacrolimus in liver transplantation. Advagraf is a
once-daily formulation of tacrolimus (ODTac), originally de-
veloped to improve adherence which is an important risk fac-
tor for rejection and graft loss [1]. Tacrolimus is characterized
by a narrow therapeutic window and highly variable pharma-
cokinetics necessitating therapeutic drug monitoring (TDM)
to individualize the dose and prevent rejection or toxicity such
as leukopenia and renal toxicity [2]. Tacrolimus is primarily
metabolized by the cytochrome P450 enzymes CYP3A4 and
CYP3A5 [3]. Differences in activity of metabolizing enzymes
are responsible for a large part of the variability in
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pharmacokinetics [3]. Genetic polymorphisms in CYP3A4
and CYP3A5 are known to cause clinically relevant variability
in tacrolimus pharmacokinetics in solid organs transplantation
[4]. However, since CYP3A4 and CYP3A5 enzymes are both
expressed in liver and intestine, in liver transplantation, both
genetics of the donor and recipient are of importance. Several
studies investigated the role of genetic variants encoding for
CYP3A5 in tacrolimus pharmacokinetics in liver transplant
recipients [5–11] but were primarily conducted in pediatric
and Asian populations. Both donor and recipient CYP3A5
genotype influenced tacrolimus pharmacokinetics in these
studies. CYP3A4*22 was only investigated in two different
studies in pediatric and Asian liver transplant recipients [6,
12]. Tacrolimus is also a substrate of P-glycoprotein
(ABCB1); however, to date, no clinically relevant polymor-
phisms have been discovered [13, 14] and therefore ABCB1
polymorphisms are not included in the scope of the current
study. TDM of ODTac is generally performed using trough
concentrations (Ctrough). However, in theory, most informative
for true exposure is the area under the blood concentration
versus time curve (AUC). This choice has a practical aspect
since TDM based on trapezoidal AUC is more laborious for
the clinic and inconvenient for the patient since multiple con-
centration markers are needed for accurate AUC calculation.
A limited sampling strategy could help influence the choice of
performing TDM based on Ctrough or AUC. Limited sampling
models have been developed for twice-daily tacrolimus [15]
in liver transplant recipients and for ODTac in renal transplant
recipients [16]; however, whether these are also applicable for
ODTac in liver transplant recipients is unknown. The primary
objective of this study was to develop a population pharma-
cokinetic model of ODTac in stable liver transplant recipients
and to evaluate the effect of CYP3A5*3 and CYP3A4*22 of
both donor and recipient on tacrolimus pharmacokinetics for
initial dose differentiation. The secondary objective was to
develop a limited sampling strategy to enable prediction of
ODTac exposure in liver transplant recipients in an efficient
way and to compare it with widely used Ctrough monitoring.
Methods
Patients During a prospective study, clinical data were col-
lected from 66 stable liver transplant recipients treated with
immunosuppressive therapy based on once-daily tacrolimus
(Advagraf®, Astellas, Leiden, The Netherlands, further re-
ferred to as ODTac) after recent conversion from twice-daily
tacrolimus (Prograft®). The DNA of recipient and donor was
available for 49 patients. These 49 patients were included for
the development of the population PK model and covariate
analysis. The donor DNAwas not available from the remain-
ing 17 patients. Inclusion criteria of the subjects were at least
18 years old, stable daily dose of twice-daily tacrolimus for at
least 3 months, no infections or other complications, bilirubin
and albumin levels within clinical reference range, and stable
graft function at the moment of conversion. The study was
approved by the Medical Ethics Committee of Leiden
University Medical Center and patients gave written informed
consent. ODTac therapy was started at the same daily dose as
of twice-daily tacrolimus. Routine TDM samples were obtain-
ed (at least) 2 weeks after conversion from twice-daily tacro-
limus to ODTac.
Bioanalytics TDM during the study was performed on the
basis of trapezoidal rule (kinfit MW/Pharm®), blood concen-
tration at t = 0, 1, 2, 3, 4, and 6 h usingMW/Pharm version 3.5
(Mediware, Groningen, The Netherlands) [17]. Quantification
of tacrolimus TDM samples in whole blood with LC-MS/MS
was performed with a validated assay capable of analyzing
everolimus, sirolimus, cyclosporine, and tacrolimus simulta-
neously. Details concerning the LC-MS/MS system are pro-
vided in Supplementary File 1. The lower limit of quantifica-
tion for tacrolimus was 0.4 μg/L. Assay performance, in terms
of limits of quantification, was in agreement with the guide-
lines regarding bioanalytical method validation of Shah et al.
[18]. Supplementary Table 1 shows the samples distribution.
Genotyping assays DNA was isolated from EDTA blood
from liver transplant recipients and from donor spleen or liver
[19]. CYP3A4*22 was determined with TaqMan 7500
(Applied Biosystems, Nieuwerkerk aan de IJssel,
The Netherlands) with a custom designed assay, according
to the manufacturers’ protocol. CYP3A5*3 was determined
wi th Pyrosequencer 96MA (Isogen, I Jsse ls te in ,
The Netherlands). Further details with regard to the genotyp-
ing protocol are provided in Supplementary Table 2. All allele
frequency distributions were in Hardy–Weinberg equilibrium.
To explore the combined effect of both recipient and donor
genotypes, the following combinations were made for
CYP3A5: C1, donor and recipient are CYP3A5*1 non-
carriers; C2, recipient is CYP3A5*1 carrier and donor is
non-carrier; C3, recipient is CYP3A5*1 non-carrier and donor
is carrier; and C4, both donor and recipient are CYP3A5*1
carriers. The following combinations were made for CYP3A4:
C1, donor and recipient are CYP3A4*22 non-carriers; C2,
recipient is CYP3A4*22 carrier and donor is non-carrier;
C3, recipient is CYP3A4*22 non-carrier and donor is carrier;
and C4, both donor and recipient are CYP3A4*22 carriers.
Pharmacokinetic modeling Nonlinear mixed effects model-
ing was used to estimate once-daily tacrolimus (Advagraf)
pharmacokinetic parameters from blood concentration-time
data. NONMEM (v7.2.1, Icon Development Solutions,
Ellicott City, MD) was used for modeling ODTac pharmaco-
kinetics, using PsN toolkit 3.7.6 [20] and Piranã version 2.8.1
[21] as modeling environment. Results were analyzed using
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the statistical software package R (v2.15.2). First-order condi-
tional estimation method with interaction (FOCE-I) was used
throughout the analysis. Model selection was based on statis-
tical significance, goodness of fit, and stability. Throughout
the model building process, an altered model was chosen over
a precursor model if a difference in the objective functions (−2
log-likelihood) was >6.63 (P < 0.01, with 1 degree of free-
dom, assuming an X2 distribution).
Base model
Initially, the model was developed exclusively on pharmaco-
kinetic data without covariates. The concentration-time data
were reviewed for completeness and consistency of sampling
and dosing times. Plots of observed concentration-time data
were examined. Subsequently, one- and two-compartmental
pharmacokinetic models with first-order elimination were
compared to find the best fit of the concentration-time data.
The value for bioavailability was fixed to 0.23 which was
based on literature [22]. Furthermore, the use of transit com-
partments and a lag time for drug absorption were explored.
Covariate analysis
Diagnostic plots were constructed of the random effects of
clearance (CL), distribution volume of the central compart-
ment (Vc) and absorption rate constant (Ka) versus the recip-
ient demographic (age, weight, sex, ethnicity, height, lean
body weight (LBW), ideal body weight (IBW), body surface
area (BSA), bodymass index (BMI), hematocrit, hemoglobin,
albumin, creatinine, primary diagnosis and co-medications
(also weighted residual vs. co-medications plots), and donor
and recipient pharmacogenetic (CYP3A4 and CYP3A5 poly-
morphisms) characteristics. Criteria for evaluation of co-
medication were a minimum frequency of administration
and probability of interaction based on literature. Genetic
polymorphisms were selected based on theoretical relation-
ship and minimal allele frequency (>0.10) to assure detection
of clinically relevant effects on ODTac PK. Based on these
plots, further testing in the pharmacostatistical model was per-
formed. Subsequently, selected covariate relationships were
evaluated by forward inclusion and backward deletion proce-
dure (P < 0.05 and P < 0.01, respectively). A covariate effect
was only maintained in the model if the inclusion resulted in a
reduction in random variability and improved model fit.
The influence of continuous covariates on pharmacokinetic
parameters was tested according to an allometric function. For
example, the effect of ideal bodyweight on apparent clearance
(CL/F) was tested using the following equation:
CL=F ¼ TV CLð Þ  IBW=mediancovð ÞθIBW
where TV(CL) is the typical value of clearance for a patient
with the median covariate value (mediancov) and θIBW is the
estimated influential factor for ideal body weight. The effect
of the genetic polymorphisms and other categorical covariates
was tested using the equation:
CL=F ¼ TV CLð Þ  1þ θcovð Þ
where TV(CL) represents the clearance of patients with θcov
equal to 0 (i.e., CYP3A5*3/*3 carriers or CYP3A4*1/*1) and
θcov is the estimated influential factor for the comparator
group. For instance, if the estimated value θcov is 0.3, the
clearance of the mutant group is on average 30 % higher than
the reference group. Covariates were tested for all the phar-
macokinetic parameters for which interpatient variability was
estimated.
Visual predictive check with prediction-correction
A prediction corrected visual predictive check (predcorrVPC)
was used to evaluate the performance of candidate and final
models of ODTac pharmacokinetics, by simulation of 500
simulated datasets [23]. Bin separators in the VPC were set
at the lowest densities of sample points over time, since ob-
servations were spread around nominal time points, i.e., this
positions the bins such that the periods with densest sampling
were in the middle of the bins. Shrinkage in between subject
variability (BSV) and residual errors was automatically calcu-
lated by NONMEM v7.2.1. to assess the informativeness of
the data for using individual predictions in the evaluation of
model fit. The distribution (median and 10th and 90th percen-
tiles) of the simulated concentration-time courses was com-
pared with the distribution of the observed values in the orig-
inal dataset. Differences and overlap of the simulated and
original distributions indicated the accuracy of the identified
model.
Limited sampling strategy
Patients and data collection
For the development of a limited sampling strategy, 66 AUCs
from 66 different patients were available, consisting of the 49
patients used in covariate analysis and an additional 17 pa-
tients of whom no DNAwas available. Demographic param-
eters of these 66 patients are presented in Table 1.
Pharmacokinetic profiles consisted of six blood samples col-
lected over 6 h (before dose and 1, 2, 3, 4, and 6 h postdose).
Pharmacokinetic and statistical analysis
For the development of a limited sampling model (LSM), we
calculated the predictive performance of different limited sam-
pling methods (limited sampling models and a limited
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sampling formula). BTrue^ exposure (FULL AUC24) was cal-
culated using post hoc estimation in NONMEMwith the final
model (AUC24 = ((DOSE*F)/CL). LSM AUC24 was calculat-
ed by selecting several concentration-time points and combi-
nations of time points and fitting the data points with post hoc
estimation in NONMEM with the final model. Subsequently,
the FULL AUC24 and LSM AUC24 of all individuals were
compared. Since Ctrough is widely used in TDM also, a limited
sampling formula (LSF) by means of a linear regression equa-
tion of Ctrough vs. FULL AUC24 was calculated to show the
difference between the limited sampling formula and a limited
sampling model. Pearson correlation coefficient test was per-
formed to determine the correlation between FULL AUC24
and limited sampling method AUC24. To evaluate the perfor-
mance of the limited sampling methods, the 17 additional
patients were also evaluated separately and compared with
the overall results. The formulas of the used predictive perfor-
mance measures are presented in Supplementary Table 3.
Results
Patients, pharmacokinetic, and pharmacogenetic data
Forty-nine adult liver transplant recipients, 31 men, and 18
women were included for the development of the population
PKmodel and covariate analysis. The majority was Caucasian
(92 %). Mean age was 54 ± 11 years (range, 29–69 years).
Mean bodyweight was 77.5 ± 11.8 kg (50–121 kg). The
dataset consisted of 282 samples. Demographic characteristics
Table 1 Clinical characteristics
Population pharmacokinetics and pharmacogenetics model dataset Limited sampling dataset
Recipient characteristics Number (proportions) Mean ± SD Median (range) Number (proportions) Mean ± SD Median (range)
Male 31 (63 %) 41 (62 %)
Female 18 (37 %) 25 (38 %)
Age (years) 54 ± 11 55 (29–69) 54 ± 11 55 (29–69)
Caucasian 45 (92 %) 59 (89 %)
Weight (kg) 84 ± 18 84 (50–131) 83 ± 17 82 (50–131)
Body Surface Area(m2) 2 ± 0.23 2 (1.5–2.6) 2.0 ± 0.23 2.0 (1.5–2.6)
Lean Body Mass (kg) 59 ± 10 59 (40–80) 59 ± 9.8 59 (40–80)
Ideal Body Weight (kg) 66 ± 7 68 (51–80) 66 ± 7.5 68 (51–82)
Height (cm) 173 ± 8 174 (155–190) 173 ± 9 174 (155–193)
Creatinine (μmol/L) 95 ± 26 97 (41–191) 97 ± 27 96 (41–191)
Albumin (g/L) 45 ± 3 45 (35–54) 45 ± 3 45 (35–54)
Hemoglobin (mmol/L) 8.48 ± 0.99 8.6 (6–10.2) 8.5 ± 1.0 8.6 (5.7–10.8)
Hematocrit (L/L) 0.42 ± 0.04 0.42 (0.30–0.50) 0.42 ± 0.04 0.42 (0.29–0.52)
Primary diagnosis
Alcoholic liver disease 12 (24.5 %) 16 (24 %)
Hepatitis B 1 (2 %) 5 (8 %)
Hepatitis C 4 (8 %) 6 (9 %)
Primary sclerosing cholangitis 9 (18 %) 10 (15 %)
Primary biliary cirrhosis 2 (4 %) 2 (3 %)
Nonalcoholic steatohepatitis 3 (6 %) 3 (5 %)
Wilson’s disease 1 (2 %) 3 (5 %)
Cystic liver disease 4 (8 %) 5 (8 %)
Hepatocellular carcinoma 1 (2 %) 1 (2 %)
Cryptogenic liver disease 2 (4 %) 2 (3 %)
Auto-immune hepatitis 1 (2 %) 1 (2 %)
Other 9 (18 %) 12 (18 %)
Exposure
Advagraf dose (mg) 3.6 ± 2.2 3 (0.5–14) 3.5 ± 2.0 3 (1–14)
Advagraf AUC24 (μg*h/L) 170 ± 55 162 (72–330) 164 ± 53 162 (50–330)
Concentrations (μg/L) 8.5 ± 3.7 8.1 (1.8–20.7) 8.3 ± 3.7 8 (1.3–20.7)
Renal function
Creatinine clearance (mL/min)a 87 ± 24 87 (33–120) 85 ± 23 85 (33–120)
a MDRD when <60 mL/min, Cockgroft Gault when >60 ml/min (cutoff 120 ml/min), AUC24 = area under the blood concentration-time curve (24 h)
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and details about the distribution of dosage and exposure are
found in Table 1. Genotype distributions for CYP3A5*3 and
CYP3A4*22 are presented in Table 2.
Structural model development
The pharmacokinetic data of once-daily tacrolimus was best
described by a two-compartmental model with delayed first-
order absorption and first-order elimination from the central
compartment. The delayed absorption of once daily tacroli-
mus was best described with three transit compartments: a
first-order rate constant describing the transfer from the dose
compartment into the transit compartments and finally into the
central compartment (Fig. 1). Random effect parameters for
interindividual variability in clearance (CL), volume of central
compartment (Vc), and rate of absorption (Ka) were identified.
Thereafter, the random effects were tested for structural rela-
tionship with dose and time to create a model with unbiased
and randomly distributed random effects for covariate analy-
sis. The shrinkage for random effect parameters on CL/F
(0 %) Vc/F (10 %) and Ka (15 %) was small which supports
unbiased covariate inclusion of the final model. The structural
pharmacokinetic model indicated an apparent clearance (CL/
F) of 4.77 L/h, an apparent central distribution volume of
87.3 L (Vc/F) and an apparent peripheral distribution volume
of 142 L. The absorption rate constant was 3.65 h−1.
Intercompartmental clearance was 14.1 L/h. The pharmacoki-
netic data showed interindividual variability in CL/F of
45.4 % with a range of 1.17–17.2 L/h.
Covariate analysis
Demographics
The base model was used for the demographic and genetic
covariate analysis. Diagnostic plots of random effects of the
pharmacokinetic parameters in the initial model against age,
weight, sex, hematocrit, hemoglobin, albumin, height, creati-
nine, IBW, BSA, BMI, LBW, co-medication, primary diagno-
sis, and ethnicity were built. Plots of weighted residuals versus
co-medications were also constructed in case there were
changes in concurrent medication regimens. The evaluated
Table 2 Genotype frequencies in studied population (n = 49)

































CYP3A5: C1 donor and recipient are CYP3A5*1 non-carriers; C2, re-
cipient is CYP3A5*1 carrier and donor is non-carrier; C3, recipient is
CYP3A5*1 non-carrier and donor is carrier; and C4, both donor and
recipient are CYP3A5*1 carriers. For CYP3A4, C1 donor and recipient
are CYP3A4*22 non-carriers; C2, Recipient is CYP3A4*22 carrier and
donor is non-carrier; C3, Recipient is CYP3A4*22 non-carrier and donor
is carrier; and C4 both donor and recipient are CYP3A4*22 carriers.
Fig. 1 Schematic representation
of the linear two-compartment
model with first-order absorption
and elimination of once daily
tacrolimus (Advagraf) including
the transit compartments to
describe the absorption phase
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co-medications can be found in Supplementary Table 4. Only
IBW and height showed a significant relationship in the uni-
variate covariate analysis (P < 0.05), however, in the multi-
variate analysis (P < 0.01), these covariates were not signifi-
cant. The following were not significant covariates on CL/F,
Vc/F, or Ka: age, weight, sex, hematocrit, hemoglobin, albu-
min, creatinine, BSA, BMI, LBW, co-medication, primary
diagnosis, and ethnicity.
Pharmacogenetics
Diagnostic plots were created of random effects of CL, Vc,
and Ka against genetic polymorphisms in CYP3A4 and
CYP3A5. The summary of the results of the effect of
CYP3A4*22 and CYP3A5*3 on tacrolimus clearance is pre-
sented in Table 3 and graphically shown in Figs. 2 and 3.
CYP3A4*22 was not significantly associated with tacrolimus
CL/F. In contrast, CYP3A5*3 showed a significant effect
(P < 0.05). Recipients with a genotype with at least one in-
creased activity allele had an average 38 % higher clearance
compared to non-carriers. Patients with a donor liver carrying
at least one increased activity allele had an average 38 %
higher clearance compared to non-carriers. Furthermore,
when combining both donor and recipients genotype, C2,
C3, and C4 showed higher clearance compared to C1 (33,
33, and 71 %, respectively) (P < 0.01). The population phar-
macokinetic parameters obtained with the base and final mod-
el are presented in Table 4.
The evaluation of the precision of the pharmacokinetic pa-
rameters was performed with 1000 bootstrap replicates. The
percentage of successful runs was 84 %. Moreover, the pa-
rameter estimates of the non-successful runs were analyzed
and did not deviate from the parameter estimates of the suc-
cessful runs. The mean values for all fixed effect parameters
were within 15 % of those obtained by the final model, indi-
cating good reliability (Table 4). Since different dosages were
used during the study, the performance of the model was eval-
uated with a predictive corrected visual predictive check [15]
(Fig. 4). Predictive and observed intervals (10, 90, and medi-
an) are almost identical, showing good predictive performance
of the final model.
In Fig. 5, the Ctrough and FULL AUC24 correlation is pre-
sented with the Ctrough and corresponding FULL AUC24.
Although a relatively good correlation is found between
Ctrough and AUC24, a relatively large amount of patients re-
mains at risk for under or over exposure. The Ctrough target
range (4–6 μg/L) corresponds with a wide AUC24 range and
vice versa. For instance, an AUC of around 160 μg*h/L
(±20 % range, 128–192 μg*h/L) corresponds with a Ctrough
of 3.8 but also with a Ctrough of 9.5 μg/L.
Development of limited sampling model
The results of the development of a LSM and the LSF of
Ctrough are shown in Fig. 6 and Supplementary Table 5.
Predictive performance measurements used are the percentage
of predicted AUC’s within a 15 % range of the Btrue^ AUC,
discordance (%) (meaning a predicted AUC leading to incor-
rect dose change), different ways of describing bias, and im-
precision (MPE,MAPE, and RSME) and correlation. Figure 6
shows results of four LSMs, both regression lines with 95 %
CI as measurements of predictive performance. The limited
sampling formula of Ctrough (22.213*Ctrough + 47.983) for
once-daily tacrolimus in predicting systemic exposure had a
moderate correlation with full trapezoidal AUC24 (a discor-
dance of 18.2 %, a mean absolute percentage prediction error
of 13.3 %, and R2 = 0.72). The best single point marker was
Ctrough (discordance, 12.1 %; mean absolute percentage
Table 3 CYP3A4 & CYP3A5
covariate analysis results Covariate tested ΔOFV P value Mean value (%) 95 % CI
Advagraf base model
+ Recipient CYP3A4*22 1.330 0.249 17 −9 to 43
+ Donor CYP3A4*22 0.391 0.532 0 −29 to 28
+ CYP3A4*22 combination 2.036 0.565 C1 0 −16 to 16
C2 12 −17 to 41
C3 −16 −50 to 18
C4 19 −19 to 56
+ Recipient CYP3A5*3 5.551 0.018 38 6 to 70
+ Donor CYP3A5*3 4.54 0.033 38 5 to 71
+ CYP3A5*3 combination 9.106 0.003 C1 0 −15 to 15
C2 33 −4 to 71
C3 33 −8 to 74
C4 71 31 to 110
ΔOFV(delta Objective Function Value) >3.84 (P < 0.05) and >6.64 (P < 0.01, chi-square test), Mean Value = the
percentage deviation compared to the reference group.
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prediction error, 11.42 %; R2 = 0.78). The best two point
markers were Ctrough and C3 (discordance, 3.0 %; mean abso-
lute percentage prediction error, 5.2 %; R2 = 0.88). The best
three point markers were Ctrough, C2, and C3 (a discordance of
1.52 % and a mean absolute percentage prediction error of
7.61 %, and R2 = 0.97). The widely used Ctrough showed less
performance with LSF and LSM compared to the two point
markers Ctrough and C3. These results were confirmed when
evaluating the limited samplingmodels using only the 17 liver
transplant recipients which were not used for the development
of the population pharmacokinetic model as showed in
Supplementary Table 5 below.
Discussion
The pharmacokinetics of ODTac in stable liver transplant re-
cipients is best described by a two-compartmental model with
Fig. 2 Boxplots representing the average once-daily tacrolimus apparent
clearance (L/h) of the different genotype groups with error bars and the
number of patients in each group. CYP3A4 (*1/*1 = CYP3A4*22 non-
carriers, *1/*22 or *22/*22 = CYP3A4*22 carriers. CYP3A4
combination: C1 donor and recipient are CYP3A4*22 non-carriers; C,:
recipient is CYP3A4*22 carrier and donor is non-carrier; C3, recipient is
CYP3A4*22 non-carrier and donor is carrier; and C4, both donor and
recipient are CYP3A4*22 carriers. *significant
Fig. 3 Boxplots representing the average once-daily tacrolimus apparent
clearance (L/h) of the different genotype groups with error bars and the
number of patients in each group. CYP3A5 (*1/*3 or *1/*1 = CYP3A5*1
carriers, *3/*3 = CYP3A5*1 non-carriers), CYP3A5 combination: C1
donor and recipient are CYP3A5*1 non-carriers; C2, recipient is
CYP3A5*1 carrier and donor is non-carrier; C3, recipient is CYP3A5*1
non-carrier and donor is carrier; and C4, both donor and recipient are
CYP3A5*1 carriers. *Significant
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first-order absorption and lag time. The delayed absorption
was best described with three transit compartments. This
study shows for the first time that ODTac pharmacokinetics
is not significantly influenced by CYP3A4*22. In contrast,
CYP3A5 genotype of both donor and recipient influences
ODTac pharmacokinetics to a clinically relevant extent. Our
Table 4 Summary of population pharmacokinetic parameter estimates from the base and final model with relative standard error and shrinkage (%)
and parameter estimates from 1000 bootstrap replicates with 95 % CI
Base model Final model 1000 bootstrap runs
PK parameter Mean value RSE(%) Shrinkage (%) Mean value RSE(%) Shrinkage (%) Median value 95 % CI
CL (L/h) 4.77 7 4.21 8 4.22 3.58 to 4.97
F (fixed) 0.23 – 0.23 – 0.23 –
Vc (L) 87.3 16 88.3 12 82.2 56.6 to 110.8
Q (L/h) 14.1 20 14 22 14.8 11.0 to 26.5
Vp (L) 142 28 145 41 131.5 86.8 to 348.4
Ka (h-1) 3.65 10 3.76 10 3.61 2.81 to 4.67
Cyp3A5*3 on CL
C1 (Reference group)(%) 0 0 −15 to 15
C2 (%) 33 32.3 −2.1 to 81.4
C3 (%) 33 30.5 −7.0 to 90.0
C4 (%) 71 67.7 35.1 to 121.3
Interindividual variability
IIV CL (CV%) 45.4 14 0 42.8 13 0 41.6 31.3 to 53.9
IIV Vc (CV%) 86.2 14 10 86.3 14 9 87.3 63.6 to 133.1
IIV Ka (CV%) 67.4 15 16 65.9 14 15 64.9 45.1 to 91.7
Random residual variability
σ1 (proportional error (%)) 13 9 23 13 8 23 12.5 10.4 to 14.6
Fig. 4 Prediction corrected
visual predictive check with 80 %
prediction interval. The observed
concentrations are shown as
closed circles. The lines with
round circles represent the
observation intervals. The solid
lines represent the prediction
intervals. The shaded areas
around the prediction intervals
represent the 95 % confidence
interval around each of the
prediction interval
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data indicate that both donor and recipient genotype should be
considered when establishing an initial ODTac dose of liver
transplant recipients. The contribution of the intestine
CYP3A5 genotype (recipient) and liver genotype (donor) to
tacrolimus pharmacokinetics was comparable. Without con-
sidering the genotype, recipients engrafted with a CYP3A5*1
carrying liver could be at risk of tacrolimus underexposure.
This is also technically feasible since tacrolimus is often initi-
ated several days posttransplantation, enabling sufficient time
to genotype the donor liver. ODTac pharmacokinetics was not
significantly influenced by weight, age, sex, hematocrit, he-
moglobin, albumin, height, BMI, BSA, LBW, primary diag-
nosis, co-medication, and ethnicity. Furthermore, the develop-
ment of a limited sampling model resulted in identification of
a three point concentration marker for accurately predicting
ODTac exposure.
In this study, the mean apparent clearance and apparent
distribution volume of the central compartment of ODTac
were 4.77 L/h and 87.3 L, respectively. The PK parameter
estimates found in this study are in agreement with those
(CL/F = 5.72 L/H) found by Yang et al. [25] and Woilard
et al. (CL/F = 4.6 L/H if F = 0.23) [16] when taking
differences in patient population (Asian, pediatric vs. adult
Caucasian) and differences in modeling into account.
The relationship between ethnicity and clearance as found
in previous studies [26, 27] could not be identified in our
study. This is most likely caused by the lack of data on eth-
nicity of the donor, and the majority (92 %) of the recipients
was of Caucasian origin. The fact that we found no effect for
concomitant medications is probably caused by the fact that
the medications previously found to be of influence on tacro-
limus clearance [3] were not administered to our liver trans-
plant recipient population. Prednisolone was administered in
too low doses to be of influence (≤10 mg). Although
established before [28, 29], hematocrit and hemoglobin were
not identified as a significant covariate in this analysis, most
likely explained by the relative narrow range within the patient
population (0.3–0.5 L/L and 6–10.2 mmol/L, respectively).
This is the first comprehensive study investigating the ef-
fect of CYP3A4*22 and CYP3A5*3 of both donor and recip-
ient on ODTac pharmacokinetics in stable adult Caucasian
liver transplant recipients. These polymorphisms were studied
before in relation to pharmacokinetics of everolimus, tacroli-
mus, and cyclosporine in renal transplant recipients [30, 31].
Fig. 5 AUC24 correlation of PK
profiles of 66 different patients
(dose range 1–14 mg). Dotted
lines crossing x-axis represent
Ctrough target area. Dotted lines
crossing the y-axis represent the
20 % deviation area from the
target AUC24 of 160 μg*h/L
(128–192 μg*h/L). AUC24 = area
under de blood concentration-
time curve from time zero to 24 h
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For tacrolimus clearance, the relationship to CYP3A5 geno-
type has been identified previously [5, 6, 30, 32] and has been
adopted in clinical practice in some transplantation centers.
However, CYP3A4*22 has shown less conclusive results
[30, 33, 34]. In liver transplant recipients, CYP3A4*22 was
only investigated in an Asian population where no mutations
were identified [12]. The limited effect of CYP3A4*22 is
probably also masked by the more dominant effect of
CYP3A5*3. Allele frequencies found in our dataset were
similar to those published previously [35]. The remaining var-
iability of our final model was 42.8 % (a sum of inter- and
intraindividual variability) and reflects the wide interindivid-
ual variability in CYP3A4/5 expression [36]. Based on our
result, we propose to implement genotyping of both donor
and recipient to establish an initial dose for ODTac in liver
transplant recipients. When aiming for an AUC24 of for in-
stance 320 μg*h/L (Ctrough 10–12 μg/L), this would mean an
initial dose of 6 mg ODTac for non-CYP3A5*1 carrying liver
c d
a b
Fig. 6 Regression line (dotted lines) plots of limited sampling methods
with 95 % confidence intervals (solid lines). a Predictive performance of
Ctrough as limited sampling formula, b predictive performance of Ctrough
with as sampling model, c predictive performance of Ctrough,3 as limited
sampling model, d predictive performance of Ctrough,2,3 as limited
sampling model
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transplant recipients, 7.5 mg ODTac for CYP3A5*1 carrying
recipients engrafted with a CYP3A5*1 non-carrying liver or
vice versa, and 10 mg ODTac for CYP3A5*1 carrying recip-
ients engrafted with aCYP3A5*1 carrying liver. Future studies
should investigate whether genotype-based dosing also leads
to improved clinical endpoints such as lower rejection rates
and improved graft survival.
In the present study, a large number of concentration-time
data was used for the population pharmacokinetic analysis.
However, our study has some limitations: Interoccasion vari-
ability could not be established since ODTac AUC-
measurements were only performed on one occasion.
Concentrations up to 6 h were collected and not up to 24 h.
Nevertheless, the PK parameters found were in accordance to
previously reported ODTac PK studies [6, 16] which did not
have these disadvantages. Furthermore, data collected from
stable liver transplant recipients were used. In general, phar-
macokinetics shortly after transplantation is more variable.
Using stable liver transplant recipients for this analysis how-
ever results in a more unbiased view on the specific genotype
contribution on ODTac pharmacokinetics. However, confir-
mation of the current findings in unstable liver transplant re-
cipients would strengthen our conclusions. Furthermore, a
larger study could help to narrow down the 95 % confidence
intervals of the genotype effects.
Ctrough monitoring of ODTac is globally widely adopted.
Besides the higher impact of assay variability when using one
marker to predict ODTac systemic exposure, the correlation
between Ctrough and AUC24 is not optimal as shown in the
results and could theoretically lead to therapy failure when
exposure is 20 % higher or lower as intended [37].
Suboptimal predictive performance of a TDMmarker can lead
to incorrect dose adjustments resulting in exposure outside the
target range. Using trapezoidal, AUC24 has the disadvantage
of requiring a relatively high number of blood samples to
reach good predictive performance which is a very invasive
and inconvenient way of performing TDM.A good alternative
is the use of a LSM with good predictive performance.
Since correlation coefficient can be misleading bias, impre-
cision was calculated to assess the performance of the differ-
ent LSMs according to the guidelines proposed by Sheiner
and Beal [24]. In our study, Ctrough monitoring had a worse
performance in estimating AUC24 when using LSF and LSM
as compared with Ctrough,2,3 in LSM. Especially, the LSF re-
sulted in a 27 % higher percentage of patients outside of the
15 % radius of the FULL AUC24 and a 16.7 % rise in discor-
dance. Ctrough,2,3 and Ctrough,1,3 showed comparable perfor-
mance and are both suitable as limited sampling model.
These results were confirmed with limited sampling evalua-
tion of 17 patients which were not used for the development of
the final model. In summary, using the three point markers
Ctrough, C2, and C3 as limited sampling model is the best op-
tion, when taking predictive performance and inconvenience
of the sampling for both patient and the clinic into account.
The three-point LSM marker Ctrough,2,3 and comparable re-
sults of Ctrough,2,3 are in accordance with what previously
has been found for ODTac in renal transplant recipients [16].
In conclusion, this study shows that the population phar-
macokinetics of ODTac in adult liver transplant recipients is
best described by a two-compartment pharmacokinetic model
with delayed absorption described by three transit compart-
ments. CYP3A5 genotype but not CYP3A4 genotype of both
donor and recipient should be taken into account to establish
an initial dose for once-daily tacrolimus. Tacrolimus blood
concentrations measured at 0, 2, and 3 h postdose can be used
to accurately estimate ODTac systemic exposure, a clear im-
provement compared to the widely used Ctrough monitoring.
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